Want to see KR:326030 full AI Analyst Report?
Top Page
SK Biopharmaceuticals Co., Ltd.
(326030)
Select Model
Select Model
Rating:69Neutral
Price Target:
$82,016.00
Action:N/A
Date:10/28/26
The score is primarily driven by strong financial performance—especially improved profitability and a de-risked balance sheet—tempered by historically volatile earnings/cash flows. Technicals are a key drag as the stock remains below key moving averages with negative MACD, while valuation is moderately supportive with a mid-teens P/E.
Positive Factors
Improved Profitability
The sharp recovery to strong gross, operating, and net profitability indicates that the business model is now converting commercial activity into meaningful earnings. Continued positive revenue growth provides a foundation for sustaining margins, funding development, and reinforcing operating leverage over the next several quarters.
Negative Factors
Earnings Volatility
The movement from substantial losses to strong recent profitability shows that earnings remain sensitive to business-cycle and product-development outcomes. This volatility makes future performance harder to forecast and could complicate consistent reinvestment, staffing, and long-term capital allocation decisions.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Profitability
The sharp recovery to strong gross, operating, and net profitability indicates that the business model is now converting commercial activity into meaningful earnings. Continued positive revenue growth provides a foundation for sustaining margins, funding development, and reinforcing operating leverage over the next several quarters.
Read all positive factors
SK Biopharmaceuticals Co., Ltd. (326030) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩6.09T
Dividend YieldN/A
Average Volume (3M)95.87K
Price to Earnings (P/E)15.7
Beta (1Y)0.25
Revenue Growth38.86%
EPS Growth56.63%
CountryKR
Employees241
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)4945.34
Shares Outstanding78,313,250
10 Day Avg. Volume126,304
30 Day Avg. Volume95,873
Financial Highlights & Ratios
PEG Ratio3.28
Price to Book (P/B)12.00
Price to Sales (P/S)13.81
P/FCF Ratio56.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4,159.4
Revenue Forecast (FY)₩975.43B
SK Biopharmaceuticals Co., Ltd. Business Overview & Revenue Model
Company Description
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the...
SK Biopharmaceuticals Co., Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
88
Very Positive
Cash Flow
73
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 861.34B | 706.74B | 547.60B | 354.89B | 246.18B | 418.64B |
| Gross Profit | 791.52B | 651.67B | 504.50B | 320.81B | 208.41B | 396.31B |
| EBITDA | 235.99B | 220.89B | 100.71B | -8.73B | -125.77B | 167.68B |
| Net Income | 400.96B | 266.95B | 240.74B | -32.88B | -139.43B | 64.85B |
Balance Sheet | ||||||
| Total Assets | 1.42T | 1.20T | 1.04T | 723.17B | 664.24B | 643.65B |
| Cash, Cash Equivalents and Short-Term Investments | 381.87B | 309.48B | 324.49B | 241.12B | 305.45B | 334.34B |
| Total Debt | 48.83B | 48.92B | 184.48B | 178.05B | 155.90B | 15.74B |
| Total Liabilities | 397.00B | 372.04B | 462.83B | 402.22B | 347.68B | 199.46B |
| Stockholders Equity | 1.02T | 813.04B | 546.27B | 283.69B | 316.56B | 444.19B |
Cash Flow | ||||||
| Free Cash Flow | 243.78B | 173.64B | 81.48B | -97.45B | -165.88B | -98.86B |
| Operating Cash Flow | 251.61B | 180.53B | 94.90B | -94.20B | -159.92B | -92.87B |
| Investing Cash Flow | -44.25B | -35.42B | -10.94B | 225.27B | -95.71B | 258.97B |
| Financing Cash Flow | -38.59B | -156.68B | -4.50B | 6.62B | 134.91B | -4.65B |
SK Biopharmaceuticals Co., Ltd. Technical Analysis
Neutral
―
Price Trends
79574.00
Negative
81656.00
Negative
93401.00
Negative
Market Momentum
-685.85
Negative
54.84
Neutral
77.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:326030, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 74405.00, equal to the 50-day MA of 79574.00, and equal to the 200-day MA of 93401.00, indicating a neutral trend. The MACD of -685.85 indicates Negative momentum. The RSI at 54.84 is Neutral, neither overbought nor oversold. The STOCH value of 77.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KR:326030.
SK Biopharmaceuticals Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₩587.91B | 12.63 | ― | 0.51% | 51.28% | 124.70% | |
69 Neutral | ₩6.09T | 15.73 | ― | ― | 38.86% | 56.63% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | ₩249.70B | -2.64 | ― | ― | 84.72% | -480.97% | |
43 Neutral | ₩2.53T | -30.20 | ― | ― | 23.25% | -58.35% | |
41 Neutral | ₩48.51B | -0.23 | ― | ― | -64.38% | 10.38% |
* General Sector Average
KR:326030
SK Biopharmaceuticals Co., Ltd.
77,700.00
-37,800.00
-32.73%
KR:005690
Pharmicell Co., Ltd
9,400.00
-7,512.47
-44.42%
KR:011000
GeneOne Life Science, Inc.
2,670.00
-7,830.00
-74.57%
KR:064550
Bioneer Corporation
6,810.00
-8,690.00
-56.06%
KR:302440
SK bioscience Co.,Ltd.
32,750.00
-17,950.00
-35.40%
KR:950210
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh
4,020.00
-8,450.00
-67.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.